Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like Z*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000351	Zogenix, Inc.	06/30/2023	43376032230	Fintepla 2.2mg/mL Oral Solution; 30mL Bottle	Brand	FDA	04/03/2023	59.40	1540.80	12/29/2038	Single Source Drug	11245700	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Zogenix believes is in the public domain or otherwise publicly available.
Rx0000351	Zogenix, Inc.	06/30/2023	43376032236	Fintepla 2.2mg/mL Oral Solution; 360mL Bottle	Brand	FDA	04/03/2023	712.80	18489.60	12/29/2038	Single Source Drug	11245700	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Zogenix believes is in the public domain or otherwise publicly available.
Rx0000163	Zyla Life Sciences	03/31/2023	69344010101	Indocin (Indomethacin) Oral Suspension 25 mg per 5mL (237mL/Bottle)	Brand	FDA	01/01/2023	213.31	2367.98	None	Innovator Multiple Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	01/31/2019	Iroko Pharmaceuticals, Inc.	87000000	None	Purchase Price is an estimate of a portion of the purchase price of the product acquired from Iroko - multiple products were acquired via a single transaction.	891.98	891.98	1985	232.17	None	Some historical pricing data relates to product's previous NDC 42221-0101-01. Zyla did not own this product at time of market introduction. Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for market introduction data points. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013).
Rx0000163	Zyla Life Sciences	06/30/2023	69344010233	Indomethacin Suppository 50 mg per suppository (30 Suppository/Box)	Generic	FDA	04/15/2023	507.15	10857.15	None	Non-innovator Multiple Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. ?? (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.	None	No change.	None	01/31/2019	Iroko Pharmaceuticals	87000000	None	Purchase Price is an estimate of a portion of the purchase price of the product acquired from Iroko - multiple products were acquired via a single transaction.	2550.00	2550.00	1984	309.62	None	Some pricing data may relate to historical NDC codes for this porduct. Zyla did not own this product at time of market introduction. Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for market introduction data points. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013)
Rx0000163	Zyla Life Sciences	03/31/2023	69344011311	Oxaydo (oxycodone hydrochloride) 5 mg/1 Tablet (100 per Bottle)	Brand	FDA	01/01/2023	96.50	1071.25	03/16/2025	Single Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired in last 5 years.
Rx0000163	Zyla Life Sciences	03/31/2023	69344021311	Oxaydo (oxycodone hydrochloride) 7.5 mg/1 Tablet (100 per Bottle)	Brand	FDA	01/01/2023	144.59	1605.11	03/16/2025	Single Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired in last 5 years.
Rx0000163	Zyla Life Sciences	03/31/2023	69344014463	Sprix (ketorolac tromethamine) 15.75mg/1 Spray, 8 Sprays / Bottle (1 Bottle)	Brand	FDA	01/01/2023	44.48	493.66	None	Innovator Multiple Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired in last 5 years.
Rx0000163	Zyla Life Sciences	03/31/2023	69344014443	Sprix (ketorolac tromethamine) 15.75mg/1 Spray, 8 Sprays per Bottle (5 Bottles per Carton)	Brand	FDA	01/01/2023	222.36	2468.30	None	Innovator Multiple Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired in last 5 years.